In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals (NASDAQ:APLS), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 1 | 5 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 4 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 2 | 1 | 2 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.14, with a high estimate of $92.00 and a low estimate of $52.00. This upward trend is apparent, with the current average reflecting a 12.2% increase from the previous average price target of $68.75.
Exploring Analyst Ratings: An In-Depth Overview
An in-depth analysis...
Login or create a forever free account to read this news
Sign up/Log in